Polymer Capital Management’s Verve Therapeutics VERV Stock Holding History

Polymer Capital Management’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,854	Closed	-$201K	–	957
2025 Q2	$201K	Sell	17,854 -17,444	-49%	-$99.4K	0.02%	541
2025 Q1	$161K	Buy	+35,298	New	+$236K	0.04%	454

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Polymer Capital Management's VERV Position: Q3 2025 in Review

Polymer Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 17,854 shares — an estimated $201K sold.

Polymer Capital Management first reported a position in VERV in Q1 2025 and held it in 2 quarters. The position peaked at $201K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Polymer Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Polymer Capital Management sold 17,854 Verve Therapeutics shares in Q3 2025, an estimated $201K.
Polymer Capital Management first reported a position in Verve Therapeutics in Q1 2025 and held it in 2 quarters.
Polymer Capital Management's Verve Therapeutics position peaked at $201K in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Polymer Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.